Portfolio and Disease Areas

Nicox’s Innovative Portfolio

Led by NCX 470, a derisked product candidate with global potential

Preclinical

Clinical

NDA

Marketed

Partner

VYZULTA® Latanoprostene Bunod Ophthalmic Sol. 0.024%

Glaucoma & Ocular Hypertension

Preclinical

Clinical

NDA

Marketed

Worldwide

ZERVIATE® Cetirizine Ophthalmic Sol. 0.24%

Allergic Conjunctivitis

Preclinical

Clinical

NDA

Marketed

U.S.

China

NCX 470 NO-donating bimatoprost Ophtalmic Sol. 0.1%

Glaucoma & Ocular Hypertension

Preclinical

Clinical

NDA

Marketed

U.S. and China

Japan

China, Korea and South Est Asia

U.S. and all other territories

NCX 1728 NO-donating PDE5 inhibitor

Glaucoma (incl. Neuroprotection) Retinal conditions

Preclinical

Clinical

NDA

Marketed

Research and global licensing option agreement

Disease focus areas

Glaucoma

A major cause of blindness

Glaucoma is a disease of the optic nerve which, if left untreated, can lead to irreversible vision loss. It is currently considered to be one of the three leading causes of irreversible blindness worldwide.

Glaucoma

Glaucoma is a disease of the optic nerve which, if left untreated, can lead to irreversible vision loss. It is currently considered to be one of the three leading causes of irreversible blindness worldwide. Glaucoma is frequently linked to elevated intraocular pressure (IOP) and is often due to blockage in the drainage system located in the front of the eye. This increase in pressure may lead to damage to the optic nerve. Currently, reducing intraocular pressure remains the only way to slow the progression of the disease. Glaucoma affects millions of patients worldwide. About 3.5% of the worldwide population between 40 and 80 years are estimated to be affected by the most common form of glaucoma.

Current medications act by reducing IOP to slow the progression of the disease. It is generally accepted that every mmHg of IOP lowering results in a risk reduction disease progression of approximately 10%. Numerous eye drops are available that either decrease the amount of fluid produced in the eye or improve its flow out of the eye. 40% of patients fail to reach target IOP with existing monotherapies, risking disease progression and vision loss. Despite having well established first line therapies, including the standard of care, latanoprost, there remains an unmet need for therapy with a greater IOP-lowering efficacy that is both safe and well tolerated.

Another area of research is to develop products which would protect the back of the eye (the retina) where the optic nerve is located from damage associated with the increase in pressure, so-called “neuroprotection”.

Glaucoma affects millions of patients worldwide.

80 million

Sufferers

About 80 million people are estimated to be affected by the most common form of glaucoma.

50%

Undetected

Open-angle glaucoma, the most common form, often is accompanied by increased eye pressure. There are typically no early symptoms, which is why 50% of people with glaucoma don’t know they have the disease.

$7 billion

Global market

$7 billion, estimated to grow at 3% to 5% CAGR (Compound Annual Gross Rate)

Allergic Conjunctivitis

One of the most common eye conditions

Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis, an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids.

Allergic Conjunctivitis

Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis, an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids. It may affect one or both eyes. The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light. It is estimated that more than 75 million people suffer from allergic conjunctivitis in the United States and the estimated prevalence of allergic conjunctivitis may be between 15% and 40%.

Allergic conjunctivitis is common in people who have other signs of allergic disease, such as hay fever, asthma, and eczema. It is caused by the body’s reaction to certain substances it is allergic to.

75m

People suffering

It is estimated that more than 75 million people suffer from allergic conjunctivitis in the United States

40%

Prevalence

Of those in the United States suffering from allergic conjunctivitis, it is estimated prevalence may be between 15% and 40%

Retinal conditions

The retina is a thin, light-sensitive layer at the back of the eye that converts incoming light into electrical signals the brain can interpret as vision. When diseases affect the retina, this process is disrupted, often leading to impaired sight or even blindness.

Retinal conditions

The retina is a thin, light-sensitive layer at the back of the eye that converts incoming light into electrical signals the brain can interpret as vision. When diseases affect the retina, this process is disrupted, often leading to impaired sight or even blindness. One of the most common examples is age-related macular degeneration (AMD), which damages the macula, the central portion of the retina responsible for sharp vision. AMD occurs in two forms: a dry type, which progresses gradually as the macula thins and small clumps of waste material, called drusen, accumulate, and a wet type, which is less common but far more aggressive because abnormal blood vessels leak fluid and damage retinal tissue.

Another widespread condition is diabetic retinopathy, a complication of long-term diabetes that harms blood vessels in the retina and remains one of the leading global causes of vision loss.

Certain conditions are much rarer, such as retinitis pigmentosa, by contrast, an inherited disorder that affects roughly one in 4,000 people and gradually narrows vision over time.

Together, these conditions highlight both the broad clinical need and the specialized opportunities in retinal disease treatment.

200 million

sufferers of AMD

About 200 million people are estimated to suffer from AMD.

100 million

Sufferers of diabetic retinopathy

About 100 million people are estimated to suffer from diabetic retinopathy.

Our portfolio at a glance

Product candidates

NCX 470

Nicox’s lead clinical product candidate

NCX 470, is a novel nitric oxide (NO)-donating bimatoprost eye drop in development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. It has successfully completed two Phase 3 clinical trials and New Drug Application submissions are being prepared for the United States and China, with a separate Phase 3 program ongoing in Japan.

NCX 470

Mont Blanc and Denali Phase 3 trials completed – Whistler Phase 3b completed

Exclusively licensed to Kowa for development and commercialisation of NCX 470 in all territories except China, Korea and Southeast Asia, where NCX 470 is licensed to Ocumension.

Phase 3 clinical trials ongoing in Japan.

Expected milestones

New Drug Application submissions in preparation in U.S. and China

NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs. Bimatoprost, marketed under the brand name LUMIGAN® by AbbVie, Inc., is the leading branded PGA. PGAs are the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension.

NCX 470 has completed two Phase 3 clinical trials designed to fulfill the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China.

NCX 470 has also been studied in a Phase 2 trial, Dolomites and in a Phase 3b trial, Whistler, and a separate Phase 3 program is ongoing in Japan. Exploratory nonclinical studies in a well-defined model with optic nerve head and retina damage (ET-1-induced ischemia/reperfusion) investigated the NCX 470 effects beyond its IOP lowering properties. The results suggest that NCX 470 improves ocular perfusion and restores retinal function in damaged eyes compared to vehicle and to Lumigan^® and may therefore have protective properties for the retina. Beneficial effects of NCX 470 have additionally been demonstrated in an in vivo model of retinal cell damage (see Press Release of September 29, 2021).

NCX 470 is protected worldwide by composition of matter patents until 2029, with a potential extension of up to 5 years in the U.S. and EU and by formulation patents to 2039 in the U.S., EU, Japan and China as well other territories.

NCX 1728

Lead compound in a new class of NO-donating molecules

NCX 1728 is an NO-donating Phosphodiesterase-5 (PDE5) inhibitor in preclinical research with potential for development in glaucoma, including neuroprotection, and retinal conditions.

NCX 1728

Preclinical evaluation

Expected milestones

Potential option exercise under research and global licensing option agreement with Glaukos

NCX 1728, an NO-donating Phosphodiesterase-5 (PDE5) inhibitor, is the lead compound of a new class of NO-donating molecules in which the NO-mediated effects are enhanced and prolonged by concomitant PDE5 inhibition in the same molecule. PDE5 inhibition has been previously shown to enhance the efficacy and the duration of NO-mediated effects. This class of molecules has the potential for glaucoma and for retinal conditions and is currently being evaluated under a research and license option agreement with Glaukos.

Commercial Products

VYZULTA^®

A prostaglandin analog with one of its metabolites being nitric oxide (NO)

VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024%, indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. It is exclusively licensed worldwide to Bausch + Lomb, a leading global eye health company. VYZULTA is commercialized in more than 15 countries, including the U.S. and is also approved in a number of other countries. Nicox sold the royalty revenue from VYZULTA to Soleus Capital in October 2024.

VYZULTA^®

Launched in more than 15 countries, including the U.S.

Expected milestones:

Recurrent revenue

VYZULTA, exclusively licensed worldwide to Bausch + Lomb, is a prostaglandin analog with one of its metabolites being nitric oxide (NO). VYZULTA is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension in the U.S. At approval, VYZULTA was the first eye drop approved in the past 20 years with a novel approach to reduce IOP.

VYZULTA was launched in more than 15 countries, including the U.S. where it is covered by a composition of matter patent to 2029.

Nicox sold the royalty revenue from VYZULTA to Soleus Capital in October 2024.

For further details on VYZULTA, please visit our partner’s dedicated website www.vyzulta.com.

ZERVIATE^®

Indicated for the treatment of ocular itching associated with allergic conjunctivitis

ZERVIATE® (cetirizine ophthalmic solution), 0.24%, indicated for the treatment of ocular itching associated with allergic conjunctivitis, is commercialized in the U.S. by our partner Harrow, and in China by Ocumension Therapeutics. ZERVIATE is exclusively licensed to Ocumension Therapeutics for development and commercialization in the Chinese and the majority of the South East Asian markets.

ZERVIATE^®

Commercialized in U.S. by partner Harrow and in China by Ocumension Therapeutics

Licensed to partners across Southeast Asia and the Middle East

Expected milestones:

Recurrent revenue

ZERVIATE is a novel, patented eye drop formulation of cetirizine approved in the U.S. for ocular itching associated with allergic conjunctivitis.

ZERVIATE is commercialized in the U.S. by exclusive partner Harrow, Inc., and in China by Ocumension Therapeutics.

The ZERVIATE formulation is protected by granted patents in the U.S. to 2030 and 2032, and in Europe, Japan and Canada to 2030.

For further details on ZERVIATE in the U.S., please visit our partner’s dedicated website www.zerviate.com

Watch how our science works

Nitric oxide donation

The Nicox expertise

We have developed a leading scientific and strategic position in the therapeutic application of nitric oxide (NO)-donating compounds based on our internally-developed NO-donating research platform, specifically in ophthalmology, supported by an extensive patent portfolio.

Our NO-donating research platform produced NO-donating compounds targeting glaucoma, including VYZULTA®, our first FDA-approved product, commercialized in the United States and other countries by our exclusive global licensee, Bausch + Lomb, NCX 470, currently in Phase 3 clinical development and NCX 1728, in preclinical evaluation with Glaukos.

Nitric oxide donation

The Nicox expertise

Our research efforts focus on ocular disorders in which NO is believed to play a role, including lowering intraocular pressure (IOP) in glaucoma or in retinal health.

NO is a well-known, small, naturally occurring signaling molecule known to stimulate an intracellular enzyme, soluble guanylate cyclase (sGC), which converts guanosine triphosphate to the second messenger, cyclic guanosine monophosphate (cGMP). NO/sGC signaling pathway plays a key role in the regulation of IOP homeostasis and ocular blood flow. The NO stimulated increase in cGMP in the trabecular meshwork leads to the reduction of intracellular calcium, relaxation of the trabecular meshwork and, consequently, an increase in the outflow of the aqueous humor from the anterior segment of the eye through the primary or conventional outflow pathway. All of the foregoing events are thought to lead to lowering of IOP and enhance ocular perfusion.

The biological effects of NO in the eye may be further enhanced and/or prolonged by phosphodiasterase type-5 (PDE5) inhibitors, which inhibit the degradation of cGMP. This has led to a new class of molecules, NO-donating PDE5 inhibitors, which have the potential for development in retinal conditions and a candidate in this series is under preclinical evaluation for glaucoma and retinal conditions.

Publications

Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC Trial

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs

A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Naïve Patients

Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular Pressures

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs

NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina

NCX 470, a Nitric Oxide Donating Bimatoprost versus Latanoprost Has Greater Proportion of Subjects Achieving ≥10 mmHg IOP Decrease in Phase 3 Trial

NCX 470, a Nitric Oxide Donating Bimatoprost Compared with Latanoprost – Adaptive Design Period Results from the Phase 3 Mont Blanc Clinical Trial

Effects of NCX 470, a nitric oxide (NO)-donating bimatoprost, in an in vitro 3D-human trabecular meshwork (TM)/Schlemm’s canal (SC) tissue model

NCX 470, a nitric oxide (NO)-donating bimatoprost, preserves rabbit eyes from biochemical and functional changes associated with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of optic nerve head and retina

NCX 470, a Nitric Oxide Donating Bimatoprost, Demonstrates Non-inferiority to Latanoprost in Phase 3 Mont Blanc Clinical Trial

NCX 470 Restores Ocular Hemodynamics and Retinal Cell Physiology After ET-1-Induced Ischemia/Reperfusion Injury of Optic Nerve and Retina in Rabbits

NCX 470, a nitric oxide (NO)-donating prostaglandin analog, restores ocular hemodynamics and photoreceptor function after endothelin-1-induced ischemia/reperfusion injury in rabbits

NCX 470, a nitric oxide (NO)-donating prostaglanding analog, elicits sustained IOP-lowering and modifies aqueous humor dynamic in non-human primates

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042% and 0.065%) and Latanoprost 0.005% in Patients with Open-Angle Glaucoma or Ocular Hypertension: The Dolomites Study

Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma Francesco Impagnatiello; Elena Bastia; Nicoletta Almirante; Stefania Brambilla; Brigitte Duquesroix; Angela C Kothe; Michael V W Bergamini

NCX 470, a nitric oxide (NO)-donating bimatoprost lowers intraocular pressure in rabbits, dogs and non-human primate models of glaucoma Francesco Impagnatiello; Elena Bastia; Carol B Toris; Achim H Krauss; Ganesh Prasanna; Ennio Ongini Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5809. doi

Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E, Krauss AH. Invest Ophthalmol Vis Sci. 2015;56(11):6558-64. http://iovs.arvojournals.org/article.aspx?articleid=2461805

Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review. Constance O Okeke, Nora Lee Cothran, Desirae A Brinkley, Kamran Rahmatnejad,Frank J Rodiño, James E Deom

Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings Robert N. Weinreb, Jeffrey M. Liebmann, Keith R. Martin, Paul L. Kaufman,Jason L. Vittitow

Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension The APOLLO Study. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Ophthalmol. 2016;123:965-73.

Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: The LUNAR Study. Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Am J Ophthalmol. 2016;168:250–9.

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study Kazuhide Kawase, Jason L. Vittitow, Robert N. Weinreb, Makoto Araie For the JUPITER Study Group

Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours JOHN H.K. LIU, JOHN R. SLIGHT, JASON L. VITTITOW, BALDO SCASSELLATI SFORZOLINI, ROBERT N. WEINREB

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24h in Healthy Japanese Subjects Makoto Araie, Baldo Scassellati Sforzolini, Jason Vittitow, Robert N. Weinreb

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER study group. Br J Ophthalmol. 2015;99(6):738-45.

Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Cavet ME, Vollmer TR, Harrington KL, VanDerMeid K, Richardson ME. Invest Ophthalmol Vis Sci. 2015;56(6):4108-16. http://iovs.arvojournals.org/article.aspx?articleid=2363039

Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E. Exp Eye Res. 2011;93(3):250-5.

NCX 1728, a nitric oxide (NO)-donating PDE-5 inhibitor, but not its des-nitro derivative (NCX 1880), enhances ocular perfusion and improves photoreceptor function in rabbits with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of optic nerve head and retina

NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys Elena Bastia 1, Carol Toris 2, Jean-Michel Bukowski 3, Stefania Brambilla 1, Corinna Galli 1, Nicoletta Almirante 1, Michael V W Bergamini 4, Laura Lucarini 5, Tomas Navratil 6, Francesco Impagnatiello 1

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma Impagnatiello F., Bastia E., Toris C., Fan S., Brambilla S., Galli C., Almirante N., Bergamini M.V.W.

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma Impagnatiello F., Navratil T., Toris C.B., Bergamini M.V.W., et al.

NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs Elena Bastia,Carol B.Toris, Stefania Brambilla,Corinna Galli, Nicoletta Almirante,Michael V. W. Bergamini, Emanuela Masini, Silvia Sgambellone, Andrea M. Unser, Feryan Ahmed, Karen Y. Torrejon, Tomas Navratil, and Francesco Impagnatiello

NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) via stimulation of trabecular meshwork/Schlemm’s canal outflow facility Impagnatiello F, Bastia E, Torrejon KY, Unser AM, Ahmed F. ARVO 2018, Honolulu, Hawaii, USA

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma. Bastia E, Impagnatiello F, Ongini E, Serle JB, Bergamini MVW. Invest Ophthalmol Vis Sci. 2017;58(8):2106. ARVO 2017, Baltimore, Maryland, USA

IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits. Bastia E, Masini E, Durante M, Bergamini MVW., Ongini E, Impagnatiello F. Invest Ophthalmol Vis Sci. 2016;57(12):3031. ARVO 2016, Seattle, Washington, USA

NCX 667, a novel nitric oxide (NO) donor, lowers intraocular pressure (IOP) in ocular normotensive and hypertensive eyes of rabbits and non-human primates. Bastia E, Impagnatiello F, Almirante N, Lanzi C, Masini E, Toris C, Ongini E. Invest Ophthalmol Vis Sci. 2015;56(7):1999. ARVO 2015, Denver, Colorado, USA

Nitric oxide (NO): an emerging target for glaucoma. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Invest Ophthalmol Vis Sci. 2014;55(8):5005-15.

Portfolio and Disease Areas

Nicox’s Innovative Portfolio

Led by NCX 470, a derisked product candidate with global potential

Disease focus areas

Glaucoma

A major cause of blindness

Glaucoma affects millions of patients worldwide.

Sufferers

Undetected

Global market

Allergic Conjunctivitis

One of the most common eye conditions

People suffering

Prevalence

Retinal conditions

sufferers of AMD

Sufferers of diabetic retinopathy

Our portfolio at a glance

Product candidates

NCX 470

Nicox’s lead clinical product candidate

Expected milestones

NCX 1728

Lead compound in a new class of NO-donating molecules

Expected milestones

Commercial Products

VYZULTA®

A prostaglandin analog with one of its metabolites being nitric oxide (NO)

Expected milestones:

ZERVIATE®

Indicated for the treatment of ocular itching associated with allergic conjunctivitis

Expected milestones:

Nitric oxide donation

The Nicox expertise

Publications

Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC Trial

A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs

A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Naïve Patients

Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular Pressures

NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs

NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina

NCX 470, a Nitric Oxide Donating Bimatoprost versus Latanoprost Has Greater Proportion of Subjects Achieving ≥10 mmHg IOP Decrease in Phase 3 Trial

NCX 470, a Nitric Oxide Donating Bimatoprost Compared with Latanoprost – Adaptive Design Period Results from the Phase 3 Mont Blanc Clinical Trial

Effects of NCX 470, a nitric oxide (NO)-donating bimatoprost, in an in vitro 3D-human trabecular meshwork (TM)/Schlemm’s canal (SC) tissue model

NCX 470, a nitric oxide (NO)-donating bimatoprost, preserves rabbit eyes from biochemical and functional changes associated with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of optic nerve head and retina

NCX 470, a Nitric Oxide Donating Bimatoprost, Demonstrates Non-inferiority to Latanoprost in Phase 3 Mont Blanc Clinical Trial

NCX 470 Restores Ocular Hemodynamics and Retinal Cell Physiology After ET-1-Induced Ischemia/Reperfusion Injury of Optic Nerve and Retina in Rabbits

NCX 470, a nitric oxide (NO)-donating prostaglandin analog, restores ocular hemodynamics and photoreceptor function after endothelin-1-induced ischemia/reperfusion injury in rabbits

NCX 470, a nitric oxide (NO)-donating prostaglanding analog, elicits sustained IOP-lowering and modifies aqueous humor dynamic in non-human primates

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042% and 0.065%) and Latanoprost 0.005% in Patients with Open-Angle Glaucoma or Ocular Hypertension: The Dolomites Study

Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma Francesco Impagnatiello; Elena Bastia; Nicoletta Almirante; Stefania Brambilla; Brigitte Duquesroix; Angela C Kothe; Michael V W Bergamini

NCX 470, a nitric oxide (NO)-donating bimatoprost lowers intraocular pressure in rabbits, dogs and non-human primate models of glaucoma Francesco Impagnatiello; Elena Bastia; Carol B Toris; Achim H Krauss; Ganesh Prasanna; Ennio Ongini Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5809. doi

Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review. Constance O Okeke, Nora Lee Cothran, Desirae A Brinkley, Kamran Rahmatnejad,Frank J Rodiño, James E Deom

Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings Robert N. Weinreb, Jeffrey M. Liebmann, Keith R. Martin, Paul L. Kaufman,Jason L. Vittitow

Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension The APOLLO Study. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Ophthalmol. 2016;123:965-73.

Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: The LUNAR Study. Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Am J Ophthalmol. 2016;168:250–9.

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study Kazuhide Kawase, Jason L. Vittitow, Robert N. Weinreb, Makoto Araie For the JUPITER Study Group

Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours JOHN H.K. LIU, JOHN R. SLIGHT, JASON L. VITTITOW, BALDO SCASSELLATI SFORZOLINI, ROBERT N. WEINREB

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24h in Healthy Japanese Subjects Makoto Araie, Baldo Scassellati Sforzolini, Jason Vittitow, Robert N. Weinreb

Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Cavet ME, Vollmer TR, Harrington KL, VanDerMeid K, Richardson ME. Invest Ophthalmol Vis Sci. 2015;56(6):4108-16. http://iovs.arvojournals.org/article.aspx?articleid=2363039

Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E. Exp Eye Res. 2011;93(3):250-5.

NCX 1728, a nitric oxide (NO)-donating PDE-5 inhibitor, but not its des-nitro derivative (NCX 1880), enhances ocular perfusion and improves photoreceptor function in rabbits with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of optic nerve head and retina

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma Impagnatiello F., Bastia E., Toris C., Fan S., Brambilla S., Galli C., Almirante N., Bergamini M.V.W.

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma Impagnatiello F., Navratil T., Toris C.B., Bergamini M.V.W., et al.

NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) via stimulation of trabecular meshwork/Schlemm’s canal outflow facility Impagnatiello F, Bastia E, Torrejon KY, Unser AM, Ahmed F. ARVO 2018, Honolulu, Hawaii, USA

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma. Bastia E, Impagnatiello F, Ongini E, Serle JB, Bergamini MVW. Invest Ophthalmol Vis Sci. 2017;58(8):2106. ARVO 2017, Baltimore, Maryland, USA

IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits. Bastia E, Masini E, Durante M, Bergamini MVW., Ongini E, Impagnatiello F. Invest Ophthalmol Vis Sci. 2016;57(12):3031. ARVO 2016, Seattle, Washington, USA

Nitric oxide (NO): an emerging target for glaucoma. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Invest Ophthalmol Vis Sci. 2014;55(8):5005-15.

Cookies

VYZULTA^®

ZERVIATE^®